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Abstract
Glucocorticoids are currently the only drug treatment recognized to benefit Duchenne muscular dystrophy (DMD) patients.
The nature of the mechanisms underlying the beneficial effects remains incompletely understood but may involve an
increase in the expression of utrophin. Here, we show that treatment of myotubes with 6a2methylprednisolone-21 sodium
succinate (PDN) results in enhanced expression of utrophin A without concomitant increases in mRNA levels thereby
suggesting that translational regulation contributes to the increase. In agreement with this, we show that PDN treatment of
cells transfected with monocistronic reporter constructs harbouring the utrophin A 59UTR, causes an increase in reporter
protein expression while leaving levels of reporter mRNAs unchanged. Using bicistronic reporter assays, we further
demonstrate that PDN enhances activity of an Internal Ribosome Entry Site (IRES) located within the utrophin A 59UTR.
Analysis of polysomes demonstrate that PDN causes an overall reduction in polysome-associated mRNAs indicating that
global translation rates are depressed under these conditions. Importantly, PDN causes an increase in the polysome
association of endogenous utrophin A mRNAs and reporter mRNAs harbouring the utrophin A 59UTR. Additional
experiments identified a distinct region within the utrophin A 59UTR that contains the inducible IRES activity. Together,
these studies demonstrate that a translational regulatory mechanism involving increased IRES activation mediates, at least
partially, the enhanced expression of utrophin A in muscle cells treated with glucocorticoids. Targeting the utrophin A IRES
may thus offer an important and novel therapeutic avenue for developing drugs appropriate for DMD patients.
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Introduction
Glucocorticoid administration is currently the only drug
treatment known to offer real clinical benefit to patients suffering
from Duchenne muscular dystrophy (DMD). Glucocorticoids used
to treat DMD include prednisone [1] and its oxazoline derivative,
deflazacort [2]. DMD patients treated with glucocorticoids exhibit
delayed progression of muscle weakness [3] and remain ambula-
tory for a greater period of their lives [4]. The mechanism by
which patients benefit from glucocorticoid treatment is not fully
understood, although it is thought that the clinical benefits arise in
part from the anti-inflammatory and immunosuppressive effects of
these drugs [5]. Previous work has shown that deflazacort
treatment of the mdx mouse, a dystrophin deficient model of
DMD, can alleviate symptoms of the dystrophic pathology and
results in the stimulation of utrophin A expression in skeletal
muscle fibers [6]. This observation is important since one
therapeutic strategy for the treatment of DMD involves the
stimulation of endogenous utrophin levels in dystrophic skeletal
muscle fibers [7,8]. In this context, utrophin upregulation
represents an interesting therapeutic strategy for DMD since it is
the autosomal homologue of dystrophin, the protein missing from
DMD muscle fibers. Several previous studies have in fact shown
the ability of utrophin to functionally compensate for the absence
of dystrophin in various animal models of DMD [9–11]. Since
stimulation of utrophin expression may be one mechanism by
which DMD patients benefit from glucocorticoid treatment, it thus
becomes important to define the molecular targets through which
these drugs act to increase utrophin expression in muscle cells.
While utrophin expression can be enhanced at the transcrip-
tional level in response to deflazacort treatment in mdx mice [6],
several groups have also demonstrated that utrophin is regulated
at the translational or post-translational level in response to
glucocorticoid treatment. Indeed, it has been shown that treatment
of cultured muscle cells with glucocorticoids causes an increase in
utrophin protein expression without corresponding changes in
utrophin transcript levels [12,13]. This discrepancy between
utrophin protein and mRNA levels occurs also under other
conditions, as we first demonstrated in muscle fibers of DMD
patients and regenerating mouse muscle fibers [14]. Similar
observations have been made when examining utrophin expres-
sion in mdx skeletal muscle [15]. Thus, utrophin appears to be
regulated by translational and/or post-translational mechanisms
under diverse conditions.
Recently, we provided further evidence that translational
control can account for the large increase in utrophin protein
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the absence of concomitant changes in utrophin transcript levels
[16]. By using direct injection of monocistronic and bicistronic
reporter vectors harbouring the utrophin A 59 untranslated region
(59UTR) into mouse skeletal muscle, we showed that the utrophin
A5 9UTR contains an Internal Ribosome Entry Site (IRES) that is
quiescent in adult muscle fibers, but becomes preferentially
activated upon the stress of muscle regeneration [16]. IRES-
mediated translation is an alternative mechanism of translation
initiation that is believed to occur independently of the methyl
7
guanosine cap structure at the 59end of an mRNA. This cap-
independent mechanism of translation initiation regulates trans-
lation of specific eukaryotic mRNAs in response to stressful
conditions in cells where cap-dependent translation is compro-
mised [17]. Since glucocorticoid treatment of muscle cells results
in an increase in utrophin expression without alterations in mRNA
levels, we hypothesized that IRES-mediated translational control
is in fact the mechanism responsible for enhanced utrophin
expression under these conditions. Here, we tested this hypothesis
and demonstrate that PDN treatment enhances the activity of the
utrophin IRES that in turn allows for efficient recruitment of
utrophin mRNA into polysomes despite the overall inhibition of
protein synthesis that is caused by treatment with PDN.
Results
Glucocorticoid Treatment of C2C12 Myotubes Stimulates
Utrophin Protein Expression Without Affecting mRNA
Levels
Earlier studies have demonstrated that utrophin is stimulated at
the protein, but not mRNA level in muscle cells treated with various
glucocorticoids [12,13]. We thus treated C2C12 myotubes for
3 days with the glucocorticoid 6a-methylprednisolone-21 sodium
succinate (PDN) at a concentration previously shown to increase
utrophin protein levels by ,40% (500 nM) [13]. As expected,
Western blot analysis showed that utrophin protein levels were ,1.5
fold greater (p,0.05) inPDN- versus DMSO (control: CTL)- treated
myotubes (Figure 1A, B). In contrast to this induction upon PDN
treatment, and in accordance with previous findings [13], we
observed no increase in utrophin mRNA levels by both end point
PCR (Figure 1C, D) and quantitative PCR (Figure 4B) (p.0.05).
Similarly, utrophin promoter activity was not induced by PDN
treatment, as revealed by transient transfection experiments using a
utrophin A promoter-reporter construct (Figure 1E).
The Utrophin A 59-UTR Regulates Expression of a
Reporter Protein in Response to Glucocorticoid
Treatment
We next performed a complementary set of experiments to test
the hypothesis that PDN treatment enhances translation of
utrophin A transcripts via events targeting its 59UTR. To this
end, we transfected myoblasts with a monocistronic construct
driven by the CMV promoter that contained the utrophin A
59UTR upstream of a CAT reporter (pUtrA/CAT) (Figure 2A).
After inducing myoblasts to differentiate, we treated these cells
with DMSO (CTL) or PDN for 2–3 days. Levels of CAT reporter
protein were then measured and standardized to levels of
neomycin protein, expressed from the same plasmid via a separate
promoter. The results show that PDN treatment caused an
increase in the relative expression of CAT protein by ,1.5–2 fold
(p,0.05) in cells transfected with the pUtrA/CAT plasmid. In
contrast, CAT protein levels remained unaffected by PDN
treatment in cells transfected with the parental pCAT construct
(Figure 2B). Quantitative analysis of the levels of CAT and
neomycin mRNAs by RT-PCR revealed that relative CAT
mRNA levels were not affected by PDN treatment in muscle cells
transfected with either the pCAT or pUtrA/CAT construct
(Figure 2C). Thus, the observed increase in CAT protein
expression without concomitant induction of CAT mRNA
expression, strongly suggests that PDN treatment causes increased
translation of the UtrA/CAT mRNA.
Glucocorticoid Treatment Enhances Utrophin A IRES
Activity
In subsequent experiments, we determined whether enhanced
translation mediated by the utrophin A 59UTR in response to
PDN treatment results from induced IRES activity. For these
studies, we used bicistronic reporter constructs and assays as
described previously [16]. C2C12 myoblasts were first transfected
with either a bicistronic construct containing the utrophin A
Figure 1. Discordant expression of utrophin and its mRNA in
glucocorticoid-treated C2C12 myotubes. C2C12 myotubes were
treated with either DMSO (CTL) or 6a-methylprednisolone-21 sodium
succinate (PDN) at 500 nM for 3 days. Cells were harvested and protein
or RNA was isolated for analysis. A) Western blot analysis for utrophin
(drp2 antibody) and GAPDH. B) Quantification of the signal intensity
seen in the Western blot experiments shows that utrophin levels are
stimulated ,1.5 fold by PDN treatment. C) Representative ethidium
bromide-stained agarose gels showing utrophin PCR product amplified
from CTL- and PDN-treated cells. D) Quantification of the RT-PCR
product bands shows that utrophin mRNA levels are unchanged by
PDN treatment. Levels of utrophin mRNA are standardized to GAPDH
mRNA. Values are in arbitrary units. E) Cells were transfected with a
utrophin A promoter-reporter construct and treated as above.
Quantification of b-galactosidase activity (standardized to a co-
transfected pCAT plasmid) demonstrates that the utrophin A promoter
is not activated by PDN treatment. Transcriptional mechanisms thus
cannot explain the increased expression of utrophin protein following
PDN treatment. Mean +/2 S.E. are shown. Experiments were performed
in triplicate, n=3. *, significant differences from control (p,0.05).
doi:10.1371/journal.pone.0002309.g001
Glucocorticoid Enhances IRES
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(Figure 3A) or an empty vector control (pbGAL/CAT). Increased
expression of the downstream cistron (CAT), relative to the
upstream cistron (bGAL) provides an indication of enhanced
IRES activity. Assessment of utrophin A IRES activity in cells
treated with PDN at concentrations ranging from 5 nM to 1 mM
revealed that maximal utrophin A IRES activity was induced at
500 nM (data not shown). As shown in Figure 3B, 500 nM PDN
treatment of muscle cells transfected with pbGAL/UtrA/CAT led
to a significant ,1.5 fold increase (p,0.05) in IRES activity as
measured by an increased ratio of CAT to bGAL. This increase in
relative IRES activity of the pbGAL/UtrA/CAT transfected cells
is due to a stimulation in expression of the downstream cistron thus
reflecting a genuine increase in IRES activity (Table 1). This level
of induction in the activity of the utrophin A IRES is consistent
with the observed increase in endogenous utrophin protein levels
following treatment with PDN (See Figure 1A, 1B and [13,18]). In
contrast to the enhancement of utrophin IRES activity, the activity
of the FGF-IA [19] and FGF-II [20] IRES elements were not
enhanced by PDN treatment ( p.0.05).
We previously demonstrated that the utrophin A 59UTR
contains a bona fide IRES element, and that the reported IRES
activity as measured using bicistronic vectors was not due to the
presence of an internal promoter or spurious splicing events [16].
To ensure that the observed induction of utrophin A IRES activity
seen here in response to PDN treatment was due to a genuine
increase in cap-independent translation, we performed quantita-
tive RT-PCR analysis on cells transfected with pbGAL/UtrA/
CAT and treated with PDN or DMSO as control. Analysis of the
amplification profiles of the bGAL and CAT cDNA products
revealed no change in the proportion of bGAL to CAT cistron
RNA in PDN- versus DMSO-treated cells (Figure 3C). In
addition, we transfected a utrophin bicistronic construct lacking
the CMV promoter, p(-cmv)bGAL/UtrA/CAT [16], and found
that CAT activity was not induced by PDN treatment (p.0.05)
(data not shown). Together, these experiments indicate that the
PDN-induced increase in IRES activity is not a result of aberrant
splicing or cryptic promoter activity.
Analysis of Polysome-Bound Utrophin A Transcripts
During Glucocorticoid Treatment
Previous studies have shown that glucocorticoids can cause
inactivation of key members of the translational machinery in
muscle cells [21] and compromise protein synthesis in skeletal
muscle [22]. In order to assess whether PDN treatment of C2C12
myotubes attenuates global translation we fractionated muscle cell
lysates by sucrose density gradient centrifugation. In Figure 4A,
the optical density profiles of typical sucrose gradients are shown.
The top of the gradient contains free mRNAs and ribosomal
subunits (40S, 60S, 80S) while the bottom of the gradient contains
Figure 2. The utrophin A 59-UTR regulates translation of a reporter protein following PDN treatment of C2C12 myotubes. A)
Monocistronic reporter constructs used in these experiments. pCAT is driven by the CMV promoter, pUtrA/CAT contains the utrophin A full-length
59UTR (UtrA) subcloned upstream of the CAT reporter. C2C12 myoblasts were transfected with either pCAT or pUtrA/CAT constructs, induced to
differentiate and then treated for 3 days with PDN (500 nM) or DMSO (CTL). B) Relative CAT protein reporter activity levels. Values are shown as a
ratio of CAT reporter protein activity to neomycin (NEO) protein reporter activity. The neomycin reporter is expressed from a separate promoter on
the pCAT construct and serves as an internal control. Note the increase in CAT reporter levels in response to PDN treatment when the utrophin 59UTR
is present. C) Relative levels of CAT containing mRNA reporter transcripts, standardized to NEO reporter mRNA levels, as assessed by RT-PCR. Note
that in contrast with was is seen with reporter protein levels, CAT reporter RNA levels are unchanged by PDN treatment independent of the presence
of the utrophin A 59UTR. Values are in arbitrary units. Mean +/2 S.E. are shown representing the average of three experiments performed in triplicate.
*, significant difference from DMSO control (CTL) (p,0.05).
doi:10.1371/journal.pone.0002309.g002
Glucocorticoid Enhances IRES
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profiles demonstrated a reduction in the relative amount of
mRNAs associated with polysomal fractions in PDN-treated cells
thereby indicating an overall attenuation of protein synthesis
under these conditions (Figure 4A).
We next compared the expression profile of utrophin A mRNA
in total cellular mRNA extracted prior to sucrose density
ultracentrifugation to that of mRNA isolated from the pooled
polysome fractions of both DMSO- (CTL) and PDN-treated
myotubes. As expected (see Figure 1C and D), quantitative RT-
PCR analysis revealed that expression of utrophin A mRNA was
not changed by PDN treatment in the total cellular mRNA
samples (Figure 4B). In contrast, we observed an ,4-fold
enrichment in the levels of endogenous utrophin A transcripts
relative to GAPDH in polysome fractions from PDN-treated
myotubes versus controls (Figure 4C). This comparison between
total levels of utrophin A transcripts and their association with
polysomal fractions indicates that PDN promotes the recruitment
of utrophin A mRNA to polysomes despite a general depression in
protein synthesis. Such recruitment of utrophin A transcripts to
polysomes is further indication that PDN treatment causes a
translational induction of utrophin expression. In order to examine
the distribution of utrophin A mRNA within the polysome
fractions, we performed RT-PCR analysis on individual ,0.5 mL
fractions from the polysome enriched regions of gradients obtained
from control and PDN-treated cells (fractions 4–12). As shown in
Figure 4D, we found that utrophin A mRNA shifted toward the
heavier polysome fractions in PDN treated cells. In contrast, the
distribution of GAPDH mRNAs in polysomes were unaffected by
PDN treatment (Figure 4D) confirming the observation that
GAPDH protein levels remain unaffected in cells treated with
PDN (Figure 1A). This shift in distribution to the heavier polysome
fractions is further indication that utrophin A translation is
enhanced by glucocorticoid treatment.
The Utrophin A 59UTR is Responsible for Recruitment of
Utrophin A Transcript to Polysomes Upon Glucocorticoid
Treatment
Based on these findings, we decided to examine whether the
utrophin A 59UTR could promote the recruitment of reporter
transcripts to polysomes upon PDN treatment. We thus transfected
myoblasts with the pUtrA/CAT or pCAT monocistronic constructs
(Figure 2A), differentiated cells into myotubes and then treated them
with DMSO or PDN. Polysome fractionation experiments were
performed as described above, and relative levels of CAT- and
neomycin-containing mRNA were quantified by RT-PCR. This
analysis revealed that PDN treatment caused a significant recruit-
ment (p,0.05) of reporter mRNA expressed from the pUtrA/CAT
construct to polysomal fractions (Figure 4E). In contrast, no change
in the levels of polysome-associated reporter mRNAs was observed
followingPDNtreatmentofcellstransfectedwiththeparentalpCAT
plasmid that lacks the 59UTR (Figure 4E). Thus, the utrophin A
59UTR plays a key role in recruiting endogenous utrophin A
transcripts to polysomes upon PDN treatment.
Mapping of the Glucocorticoid-Responsive Utrophin A
IRES Element
In order to delineate the region of the utrophin A 59UTR that
confers PDN-induced IRES activity, several truncated variants of
the utrophin A 59UTR were created and inserted into the
bicistronic vector (Figure 5A). Interestingly, PDN treatment was
found to enhance IRES activity in muscle cells transfected with
bicistronic constructs containing the first 152 or 228 nucleotides of
Figure 3. Utrophin A IRES activity is stimulated by PDN
treatment of C2C12 myotubes. A) Schematic representation of
bicistronic vector containing the utrophin A 59UTR (pbGAL/UtrA/CAT).
Regions amplified by quantitative RT-PCR in control experiments (data
presented in C) are indicated with black bars beneath the bGAL and
CAT cistrons. B) C2C12 myoblasts were transfected with either an empty
vector bicistronic reporter construct (parental), or bicistronic reporter
constructs harbouring IRES elements from FGF-IA, FGF-II and utrophin A
(UtrA).Cellswereinducedtodifferentiateandthentreatedfor3 dayswith
PDN or DMSO (CTL). Relative IRES activity is reported as a ratio of CAT
(measuring cap-independent translation), to bGAL (measuring cap-
dependent translation). Data from PDN-treated samples are standardized
to control, DMSO-treated samples. See Table 1 for individual expression
levels of the bGAL and CAT cistrons. Mean +/2 S.E. are shown
representing the average of four experiments performed in triplicate. *,
significant difference from DMSO control (CTL) (p,0.05). Note that the
effect of PDN is specific for the utrophin A 59UTR. C) Quantitative RT-PCR
using bGAL and CAT primers was performed on RNA from treated C2C12
cells transfected with pbGAL/UtrA/CAT.to exclude the possibility of
spurious splicing or cryptic promoter activity of the utrophin A IRES. The
lack of significant difference in the ratio of CAT to bGAL cDNA products
between CTL- and PDN-treated cells indicates, as expected, the presence
of an intact bicistronic transcript. The CAT/bGAL ratio is expressed as
2
2[Ct(CAT)2Ct(bGAL)] (see materials and methods for details). Values are in
arbitrary units. Mean +/2 S.D. are shown representing the average of
three experiments performed in triplicate.
doi:10.1371/journal.pone.0002309.g003
Glucocorticoid Enhances IRES
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level of induction is similar to that observed using the full-length
59UTR, i.e., construct containing nucleotides 1–508 in Figure 5B
(see also Figure 2B). In contrast, the 147–363 region of the
59UTR, as well as the 228–508 region did not confer enhanced
IRES activity in response to PDN. Further truncation of the
59UTR from its 39 end to the first 70 bases (1–70) also abolished
the responsiveness to PDN. These experiments suggested that
nucleotides 71–152 encompass the PDN-responsive IRES ele-
ment. Indeed, transient transfection of a bicistronic construct
harbouring this region demonstrated an ,1.5 fold induction in
IRES activity upon PDN treatment (p,0.05). Individual expres-
sion levels of the bGAL and CAT cistrons for each construct and
treatment are shown in Table 2. These data demonstrate that the
71–152 fragment can recapitulate the PDN-mediated induction in
IRES activity seen with the full-length 59UTR.
Figure 4. Utrophin A mRNA becomes enriched in polysomes in response to PDN treatment. A) Representative polysome profiles of C2C12
myotube cell lysates fractionated by sucrose density ultracentrifugation. C2C12 myotubes were treated with DMSO (CTL) or with PDN (500 nM) for
two days. Cells were then treated with cycloheximide and lysed. Nuclei and cellular debris were removed by centrifugation. Cell lysates were layered
on a continuous sucrose gradient. Absorbance of the gradients was measured at 254 nm from top to bottom via a peristaltic pump and RNA-
containing sucrose gradients were fractioned for a total of 12 fractions. Note the decrease in polysomal RNA in PDN-treated cells, indicating
decreased global protein translation. B) The overall change in endogenous utrophin A mRNA levels in response to PDN-treatment was measured by
qRT-PCR from total mRNA samples and is shown relative to GAPDH mRNA, n=3. C) The change in endogenous utrophin A mRNA levels in the pooled
polysome fractions from cells treated with DMSO or PDN relative to GAPDH mRNA. Note the increased presence of utrophin A transcript in the
polysome fraction of PDN treated cells, n=3. D) RT-PCR was performed to detect utrophin A and GAPDH mRNA in individual polysome enriched
fractions (fractions 4–12) of the sucrose gradient. Quantification of the amplified bands (See Materials and Methods) demonstrates a shift of utrophin
A mRNA to the heavier polysome fractions of the gradient for the PDN treated cells. Data are representative of three independent experiments.
Results were confirmed by qPCR. E) Cells were transfected with pCAT and pUtrA/CAT (see Figure 2A) and treated as above. qRT-PCR analysis of CAT
reporter transcript expression standardized to neomycin (NEO) reporter transcript expression was carried out on mRNA isolated from the pooled
polysome fractions. Note the increase in polysome-associated CAT reporter transcript in response to PDN-treatment, n=3. All values are in arbitrary
units. Mean +/2 S.E. are shown. *, significant difference from control (p,0.05).
doi:10.1371/journal.pone.0002309.g004
Glucocorticoid Enhances IRES
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Several groups have previously observed a discordant expression
patternof utrophinprotein and mRNAinresponse to glucocorticoid
treatment. Initial studies showed that treatment of cultured muscle
cells from DMD patients with the glucocorticoid dexamethasone
resulted in increased utrophin protein expression while leaving the
level of utrophin transcripts unaffected [12]. Similarly, treatment of
normal and dystrophin-deficient myotubes with PDN caused an
increase ofutrophinprotein byapproximately 40%in bothcelltypes
without altering mRNA levels [13]. Furthermore, various traditional
Chinese medicines that tested positive for glucocorticoid-like activity
can also stimulate utrophin protein expression in muscle cells [18].
Collectively, these studies suggest that gene regulation at the level of
transcription cannot explain the stimulation of utrophin protein
expression in response to glucocorticoids.
In the present study, we thus examined whether translational
regulatorymechanismscould account for the increased expressionof
utrophin protein following glucocorticoid treatment. Using multiple
and complementary approaches, we show that an enhancement of
IRES-mediated translation of utrophin A can account, at least
partially, for the increased expression of utrophin A protein in
response to PDN treatment of C2C12 myotubes. These results are
important particularly in the context of identifying small molecules
that could upregulate the endogenous levels of utrophin A in muscle
from DMD patients since they show that known drugs can indeed
increase the activity of the utrophin A IRES thereby promoting
protein synthesis from a pool of already synthesized and transla-
tionally competent transcripts. Together with our previous findings
obtained in regenerating muscle fibers [16], our current data further
illustrate that the utrophin A IRES can be activated by
physiologically relevant stimuli.
Figure 5. Elucidation of the minimal PDN-responsive utrophin
A IRES element. A) Schematic representation of bicistronic constructs
harbouring truncated regions of the utrophin A 59UTR. B) Cells were
transfected with the various bicistronic constructs, treated with DMSO
(CTL) or PDN (500 nM) for 2 days and analyzed for IRES activity,
reported as a ratio of CAT to bGAL protein reporter activity. IRES activity
in PDN treated cells is standardized to IRES activity in CTL cells. See
Table 2 for individual expression levels of the bGAL and CAT cistrons for
each construct and treatment. Mean +/2 S.E. are shown representing
the average of 3–5 independent experiments, performed in triplicate. *,
significant difference from control (p,0.05).
doi:10.1371/journal.pone.0002309.g005
Table 2. Individual bGAL and CAT expression levels for cells
transfected with bicistronic constructs harbouring truncated
regions of the utrophin A 59UTR and treated with DMSO or
PDN.
Construct Treatment bGAL CAT
Parental DMSO 100.0 +/2 1.9 100.0 +/2 2.9
Parental PDN 102.0 +/26.0 104.1 +/2 9.1
1–508 DMSO 100.0 +/2 3.3 100.0 +/2 4.8
1–508 PDN 89.5 +/2 8.6 137.5 +/2 14.3
1–70 DMSO 100.0 +/26.6 100.0 +/2 6.7
1–70 PDN 94.6 +/2 4.5 102.7 +/2 8.5
1–152 DMSO 100.0 +/2 1.4 100.0 +/2 1.6
1–152 PDN 76.0 +/2 5.7 122.5 +/2 7.2
71–152 DMSO 100.0 +/2 5.0 100.0 +/2 1.6
71–152 PDN 110.2 +/2 8.0 169.0 +/2 9.1
1–228 DMSO 100.0 +/2 2.2 100.0 +/2 3.9
1–228 PDN 75.4 +/2 5.2 120.6 +/2 3.2
228–508 DMSO 100.0 +/2 3.9 100.0 +/2 4.3
228–508 PDN 84.8 +/2 4.4 78.3 +/2 4.4
147–363 DMSO 100.0 +/2 3.8 100.0 +/2 7.2
147–363 PDN 84.1 +/2 4.9 84.8 +/2 10.7
Values correspond to the levels of relative IRES activity for the various
constructs shown in Figure 5. Values are standardized to DMSO treated
condition. Mean +/2 S.E. is shown.
doi:10.1371/journal.pone.0002309.t002
Table 1. Individual bGAL and CAT expression levels for cells
transfected with parental or utrophin A 59UTR bicistronic
constructs and treated with DMSO or PDN.
Construct Treatment bGAL CAT
Parental DMSO 100.0 +/2 2.0 100.0 +/2 0.8
Parental PDN 103.7 +/2 5.2 117.4 +/2 15.5
UtrA DMSO 100.0 +/2 3.9 100.0 +/2 6.2
UtrA PDN 97.8 +/2 3.0 167.8 +/2 19.1
Values correspond to the relative levels of IRES activity shown in Figure 3B for
cells transfected with pbGAL/CAT (Parental) or pbGAL/UtrA/CAT (UtrA). Note
the increase of CAT activity when the UtrA transfected cells are treated with




PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2309The enhancement of utrophin translation in response to PDN
treatment, as assessed by both monocistronic (Figure 2) and
bicistronic (Figure 3) reporter transfection experiments, was found
to be similar to the enhancement of endogenous utrophin protein
expression in C2C12 cells (Figure 1 A,B). Nonetheless, the increase
in utrophin protein levels might also be partially accounted for by
an increase in utrophin protein stability. We thus attempted to
assess the contribution of protein stability to the enhancement of
utrophin expression in response to PDN treatment by treating cells
with PDN and cycloheximide. Unfortunately, we found that 48–
72 hrs of cycloheximide treatment (10 mg/mL) did not signifi-
cantly reduce utrophin protein levels as assessed by western blot
(see also [23]), thus precluding a thorough assessment of the
contribution of protein stability to the enhancement of utrophin
expression by PDN treatment.
Several groups have observed that glucocorticoid treatment can
cause a reduction in global translation rates. This has in fact been
shown to occur in both cultured muscle cells as well as in skeletal
muscle of live animals [21,24–26]. The mechanisms by which
translation rates are depressed by glucocorticoids in muscle cells
have been linked to multiple pathways including inhibition of
ribosomal S6 protein kinase (P70 S6K) activity [21,26] and
dephosphorylation of eukaryotic initiation factor 4E binding
protein 1 (4E-BP1) [24,25].
Using sucrose gradient sedimentation, we also observed a
reduction in the amount of RNA present within polysomal
fractions suggesting a decrease in overall translation. In contrast,
both endogenous utrophin A transcripts and reporter mRNAs
containing the utrophin A 59UTR, became enriched within
polysomes under these conditions. It is thus interesting to note that
utrophin A translation is clearly enhanced by a treatment that
simultaneously compromises global translation rates. Several
mammalian mRNAs have been shown to exhibit enhanced
IRES-mediated translation under conditions where global trans-
lation rates are depressed such as during viral infection, mitosis
and ER stress [27–29]. Our current findings showing an activation
of the utrophin A IRES following PDN treatment, fit extremely
well with these earlier observations. Together, these results suggest
that IRES elements provide an alternative route by which specific
mRNAs continue to be translated when the proper functioning of
the cap-dependent translational machinery becomes compro-
mised.
While glucocorticoid treatment downregulates global protein
synthesis in skeletal muscle cells, several lines of evidence have
shown that it can stimulate expression of several proteins at the
translational level [30–33], including the Na
+/K
+-ATPase a1
subunit, which appears to be translationally regulated by
glucocorticoids via its 59UTR [34–36] (P.M., M.H., B.J.J.,
unpublished observations). Along these lines, it is important to
note that another steroid hormone, testosterone, has been shown
to alter IRES-mediated translation of the Fibroblast Growth
Factor 2 (FGF-II) mRNA. In this case, it was found that treatment
of an FGF-II IRES reporter mouse with testosterone activated the
FGF-II IRES in a manner dependent upon the availability of
androgen receptors [37]. Interestingly, testosterone treatment also
caused an increase in the binding and interaction of multiple
proteins from testes to an FGF-II 59UTR probe [37].
The nature of the exact mechanisms causing an increase in the
activity of the utrophin IRES following PDN treatment of muscle
cells remains for the moment unclear. Previous work by others has
shown that the increase in utrophin protein expression in response
to PDN treatment can be inhibited by simultaneously treating cells
with the glucocorticoid receptor antagonist RU486 [13,18]
thereby indicating that this increase is dependent upon activation
of the glucocorticoid receptor. It may thus be envisioned that
activation of the glucocorticoid receptor stimulates signaling
pathways that modulate the association of RNA-binding proteins
to the utrophin 59UTR, thereby enhancing IRES-mediated
translation.
A common set of RNA-binding proteins that are required for
IRES-mediated translation to occur has not been identified,
although several proteins, termed IRES-trans activating factors
(ITAFs), have been shown to modulate the activity of different
IRESes. These proteins include, for example, polypyrimidine-tract
binding protein (PTB) [38,39], the caspase-cleaved form of DAP5/
p97 (p86) [40,41] and heterogeneous nuclear ribonucleoprotein
(hnRNP) A1 [42,43]. Future studies will aim to identify the ITAFs
that mediate IRES-driven translation of utrophin during both
glucocorticoid treatment and muscle regeneration.
Treatment of DMD patients with the corticosteroids prednisone
and deflazacort slow the progression of the muscle disease.
However, this effect is not sustained and the treatment is
associated with many detrimental side effects such as weight gain,
behavioural abnormalities and osteoporosis [44,45]. Thus, gluco-
corticoid treatment does not constitute a viable long-term
treatment for DMD. Nonetheless, this treatment increases the
length of time a patient remains ambulatory while increasing
muscle mass [46] and improving pulmonary function [47,48].
Therefore, an increased understanding of the mechanisms by
which glucocorticoids improve muscle function in DMD patients is
critical in ultimately designing similar drugs with longer lasting
benefits and fewer side effects.
In addition to utrophin upregulation, it is important to note that
glucocorticoid treatment appears to benefit dystrophic muscle via
anti-inflammatory actions, including reducing macrophage and T
cell (CD2+ and CD8+) accumulation in skeletal muscle [49,50].
Therefore, the beneficial effect of prolonged glucocorticoid
treatment for DMD patients likely stems from the combinatorial
impact associated with utrophin upregulation and the anti-
inflammatory response.
Given the role of the utrophin A 59UTR in mediating the
translational response to PDN treatment demonstrated here, it
may prove useful to begin screening for drugs that target and
stimulate utrophin A IRES activity. Based on previous work
assessing the therapeutic potential of utrophin to mitigate the
dystrophic phenotype of the mdx mouse, such a drug would have
to stimulate utrophin expression levels only by ,2-fold in order to
show dramatic improvement in muscle function [51–53].
Materials and Methods
C2C12 Cell Culture and Drug Treatments
C2C12 myoblasts (American Type Culture Collection, Mana-
ssas, VA) were grown as previously described [16] on matrigel-
coated plates (BD Biosciences, Bedford, MA) in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplement-
ed with 10% Fetal Bovine Serum (Cansera, Toronto, ON,
Canada) and 100 units/mL of ampicillin/streptomycin. Cells
were kept at 37uC in a water-saturated atmosphere containing 5%
CO2. Upon reaching 80–90% confluency, the growth media was
replaced with differentiation media containing 2% Horse Serum
(Invitrogen). Cells were maintained in differentiation medium for
2–3 days. For drug treatments, 6a-methylprednisolone-21 sodium
succinate (referred to as PDN) (Sigma, St. Louis, MO) was
dissolved in DMSO to make 500 mM stocks. DMSO (used as
control; CTL) or PDN was mixed with differentiation media at
concentration of 500 nM and added to the cells [13]. Fresh media
and drug were added each day for 2–3 days of treatment before
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treatments, transient transfections of luciferase reporter constructs
harbouring the hormonal response region of the mouse mammary
tumor virus promoter [54] were performed.
Western Blot Analysis
Proteins were isolated from myotubes using a protein lysis buffer
and Western blot analysis was carried out using standard
procedures as previously described [16]. For detection of protein
levels, samples were run on 5% SDS-PAGE gels and transferred
onto PVDF membranes. The monoclonal anti-utrophin Drp-2
antibody (Vector Laboratories, Burlingame, CA) was used as at
1:500 dilution to detect utrophin, followed by incubation with a
secondary goat anti-mouse HRP antibody at 1:2500 (Chemicon
International, Temecula, CA). To detect GAPDH protein levels, a
monoclonal anti-GAPDH antibody (Advanced Immunochemical,
Long Beach, CA) was used at 1:10000, followed by a secondary
goat anti-mouse antibody at 1:5000 (Jackson Immunoresearch
Laboratories, West Grove, PA). Antibody complexes were
detected using western lightning chemiluminescent reagent (Perkin
Elmer, Waltham, MA) and exposed to Kodak BioMAX MR film
(Eastman Kodak, Rochester, NY). The net intensity of the protein
bands was quantified using Kodak digital science 1D version 3.0.2
image analysis software.
Plasmids and Transient Transfections
The bicistronic constructs pbGAL/CAT, pbGAL/UtrA/CAT
and p(-cmv)bGAL/UtrA/CAT have been previously described
[16]. Progressive deletions of the utrophin A 59UTR were
amplified by PCR and subcloned into the Xho1 site of pbGAL/
CAT. For creation of the monocistronic constructs pCAT and
pUtrA/CAT, the LacZ gene was excised from pbGAL/CAT and
pbGAL/UtrA/CAT using Not1 and the vector was re-ligated. The
1.3 kb utrophin A promoter reporter construct used has been
previously described [55]. For promoter reporter transfections, a
plasmid encoding the CAT gene driven by the SV40 promoter
(Promega, Madison, WI) was co-transfected to control for
transfection efficiency . The FGF-II IRES was PCR amplified
from an FGF-II bicistronic reporter construct (kindly provided by
Dr. A.C. Prats, INSERM, Tolouse, France) [19], and subcloned
into pbGAL/CAT. A dual luciferase bicistronic construct
harbouring the FGF-IA IRES was kindly provided by Dr. A.C.
Prats [20]. All transient transfections were carried out using
Lipofectamine 2000 (Invitrogen) while the myoblasts were 70–
90% confluent as recommended by the manufacturer. For
transfections of cells in 35 mm wells, 4 mg of plasmid DNA was
combined with 10 ml of Lipofectamine 2000. For experiments
involving transfection of monocistronic constructs and analysis of
the association of transcripts with polysomes, ten 100 mm plates
were transfected for each plasmid and drug treatment combina-
tion. Each 100 mm plate was transfected using 24 mg of plasmid
DNA combined with 60 ml of Lipofectamine 2000.
Reporter Protein Analysis
Cells were harvested in Reporter Lysis Buffer (Promega), and
assays for b2galactosidase and CAT protein reporter activity were
carried out as previously described [16,56]. For cells transfected
with monocistronic constructs, expression of neomycin was
detected using the PathoScreen NPTII ELISA assay detection
kit as recommended by the manufacturer (Agdia, Elkhart, IN). For
transient transfection experiments using the FGF-IA IRES
construct, LucR and LucF activities were measured with the dual
luciferase kit (Promega).
Polysome Fractionation Experiments
Polysome fractionation experiments were carried out according
to a previously described protocol [57]. C2C12 myotubes were
grown on 100 mm plates coated with matrigel and treated with
DMSO or PDN as described above. To isolate polysomes, cells
were treated with cycloheximide (CHX) (0.1 mg/mL) for
3 minutes in fresh differentiation media. Cells were washed twice
in PBS containing CHX and subsequently lysed in an RNA lysis
buffer (0.3M NaCl, 15 mM MgCl2, 15 mM Tris pH 7.4, 1%
Triton X-100, 0.1 mg/mL CHX, 100U/mL RNAsin). Nuclei and
cellular debris were removed by centrifugation steps of 3,000 rpm,
5 min, 4uC and then 14,000 rpm, 5 min, 4uC). Three hundred mL
of RNA was extracted from part of the lysate for total RNA
analysis. Seven hundred mL of the lysate was layered on a
continuous sucrose gradient (10–50% sucrose in 15 mM MgCl2,
15 mM Tris pH 7.4, 0.3 M NaCl). Centrifugation was carried out
at 39,000 rpm in an SW41-Ti rotor at 4uC for 90 min.
Absorbance of the gradients was measured continuously at
254 nm from top to bottom of the gradient via a peristaltic pump
operating at a flow rate of 1 ml/min. For some experiments, 1 ml
fractions were collected and polysome enriched fractions were
pooled prior to RNA extraction. To achieve better separation of
polysomes, fractions were collected in 0.5 or 1 mL intervals. For
fractions 1–3, ,1 mL was collected per fraction, while for the
polysome enriched fractions 4–12, ,0.5 mL was collected per
fraction. The polysome fractions were digested with proteinase K.
RNA was extracted by phenol chloroform extraction, and then
concentrated and treated with DNAse I using the Absolutely RNA
miniprep kit (Stratagene, La Jolla, CA). For RT-PCR analysis (see
below) on individual fractions obtained from the sucrose gradient,
the signal intensity from cDNA products of each band was divided
by the sum of the signal intensities of all bands in order to obtain
the percentage intensity of signal in each fraction.
RNA Extraction and RT-PCR Analysis
Total RNA was isolated from C2C12 cells using TRIzol reagent
(Invitrogen) as recommended by the manufacturer. TRIzol
extracted RNA was treated for 1 hour with DNAse I (Invitrogen)
to eliminate possible plasmid and genomic DNA contamination. To
quantify levels of endogenous utrophin and GAPDH mRNAs, RT-
PCR analysis was employed using previously described protocols
and primer sets [14,58]. For RT-PCR analysis on cells transfected
with the monocistronic pCAT and pUtrA/CAT constructs, CAT
was amplified using previously described primers [16] and these
levels were standardized to neomycin mRNA levels (59-TGC-
TCCTGCCGAGAAAGTAT-39;5 9-AATATCACGGGTAGC-
CAACG -39). Cycle numbers varied depending on the primers used
and they were all within the linear range of amplification. Controls
consisted ofRTmixturesinwhichtotal RNAwasreplaced bysterile,
diethylpyrocarbonate-treated water. PCR products were separated
on1.5%agarosegelscontaining ethidium bromide,and theintensity
of the signal, which is linearly related to the amount of cDNAs, was
quantified using Kodak digital science 1D version 3.0.2 image
analysis software.
In separate experiments, we also performed real-time PCR. For
these, analysis of endogenous utrophin A and GAPDH levels was
carried out using the following primer sets: utrA (59-ATCTT-
GTCGGGCTTTCCAC-39;5 9- ATCCAAAGGCTTTCCCA-
GAT-39); GAPDH (59-GGGTGTGAACCACGAGAA-AT-39;
59-CCTTCCACAATGCCAAAGTT-39). To control for aberrant
splicing or the presence of an internal promoter in the utrophin A
59UTR, qRT-PCR control experiments were conducted as
previously described to detect expression of portions of bGAL
and CAT from the bicistronic mRNA transcript [16,43,56]. For
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1 hour with DNAse I (Invitrogen) to prevent DNA contamination
from the transfected plasmid. Reverse transcription for all qRT-
PCR experiments was carried out using the First-Strand cDNA
Synthesis kit (Amersham Biosciences, Piscataway, NJ) with NotI-
d(T)18 primers. Quantitative real time PCR was performed using
the QuantiTect SYBR green PCR kit (Qiagen, Mississauga, ON,
Canada). Analysis was performed using the ABI Prism 7000
sequence detection system (Applied Biosystems, Foster City, CA)
with ABI Prism 7000 SDS Software. To control for DNA
contamination, quantitative PCR was performed directly on the
RNA samples.
Statistical Analysis
The presence of significant differences between group means
was determined using Student’s t test. The level of significance was
set at p,0.05. Means +/2 S.E. are shown throughout.
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